US 11,730,813 B2
Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
Davide Corti, Bellinzona (CH); and Hervé Bourhy, Chaville (FR)
Assigned to HUMABS BIOMED SA, Bellinzona (CH); and INSTITUT PASTEUR, Paris (FR)
Filed by HUMABS BIOMED SA, Bellinzona (CH); and INSTITUT PASTEUR, Paris (FR)
Filed on May 22, 2020, as Appl. No. 16/882,354.
Application 16/882,354 is a division of application No. 15/527,511, granted, now 10,703,801, previously published as PCT/EP2015/002305, filed on Nov. 18, 2015.
Claims priority of application No. PCT/EP2014/003076 (WO), filed on Nov. 18, 2014.
Prior Publication US 2020/0354435 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/42 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01)
CPC A61K 39/42 (2013.01) [C07K 16/10 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61P 31/14 (2018.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2760/20111 (2013.01)] 34 Claims
 
1. A method of preventing and/or treating a RABV and/or non-RABV lyssavirus infection in a subject, wherein the method comprises administering to a subject in need thereof an antibody, or an antigen binding fragment thereof, that neutralizes a lyssavirus infection, wherein the antibody or antigen binding fragment comprises heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences as set forth in SEQ ID NOs: 165-169 and 171, respectively, or in SEQ ID NOs: 165-168 and 170-171, respectively.